ArticleLeukemia2025

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.

Jan Philipp Bewersdorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.